GP2 and cancer: Recent studies revealed that patients vaccinated with GP2+ GM-CSF presented with a considerable reduction (37%) in the recurrence of cancer compared to untreated patients, and those patients that received GM-CSF alone presented with a 57% lower risk of cancer recurrence.